Video: No Evidence That AREDS Vitamins Slow GA Progression

A post hoc analysis of OAKS and DERBY data failed to support the foveal protection suggested by an earlier AREDS study.

Category	Detail
Condition	Geographic Atrophy (GA) in Age-Related Macular Degeneration
Key Mechanisms	Assessment of AREDS and AREDS2 vitamin supplementation impact on GA growth, particularly towards the fovea
Target Population	Patients with geographic atrophy secondary to age-related macular degeneration
Care Setting	Ophthalmology clinical trials and retinal specialist care settings

Post hoc analysis of OAKS and DERBY trials found no benefit of AREDS or AREDS2 vitamins on GA growth or vision loss.
Previous post hoc analysis of AREDS and AREDS2 suggested slowed GA growth towards the fovea, but this was not reproducible.
AREDS vitamins did not modify the effect of pegcetacoplan treatment or influence the development of exudative AMD.

Use multimodal imaging including fundus autofluorescence to monitor geographic atrophy progression.

Current evidence does not support AREDS or AREDS2 vitamin supplementation for slowing GA progression.
Pegcetacoplan remains a treatment option under investigation for GA.

Regular imaging to assess GA growth, especially towards the fovea, is important for disease monitoring.

No increased risk of exudative AMD development was associated with AREDS vitamin supplementation in patients treated with pegcetacoplan.

Patients with geographic atrophy enrolled in OAKS and DERBY clinical trials

AREDS and AREDS2 vitamin supplements showed no measurable benefit in slowing GA progression or enhancing pegcetacoplan effects.

Rely on updated imaging modalities such as fundus autofluorescence for accurate GA assessment.
Interpret post hoc analyses cautiously and prioritize prospective trial data for clinical decision-making.
Continue research to identify effective oral treatments for geographic atrophy.